Related Experiment Video
Updated: Feb 2, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma
Mohammed A Aljama1, M Hasib Sidiqi1, Arjun Lakshman1
1Division of Hematology and.
Abstract:
The plasma cell proliferative index (PCPI), determined by a slide technique or by flow cytometry, detects cells in the S phase of the cell cycle and is a useful prognostic tool in patients with plasma cell disorders such as multiple myeloma and amyloidosis. We conducted a retrospective review analyzing the prognostic effect of PCPI in 306 patients with smoldering multiple myeloma (SMM). Seventy-nine (26%) patients had an elevated PCPI (>0.5). An elevated PCPI predicted an inferior time to progression (median, 3.0 vs 7.1 years for those with a low PCPI; P = .0004). Within 24 months, the progression rate was significantly higher for patients with an elevated PCPI (49% vs. 20%; P < .0001). PCPI is a valuable tool in risk stratifying patients with SMM and identifies patients with earlier progression who may benefit from closer follow-up and consideration of early intervention trials.
Insights
The plasma cell proliferative index (PCPI) helps predict disease progression in smoldering multiple myeloma. An elevated PCPI indicates a higher risk of earlier progression, aiding in patient risk stratification.
Area of Science:
- Hematology
- Oncology
- Cell Biology
Background:
- The plasma cell proliferative index (PCPI) measures S-phase cells, offering prognostic value in plasma cell disorders.
- Multiple myeloma and amyloidosis are significant plasma cell disorders where prognosis is crucial.
Purpose of the Study:
- To evaluate the prognostic significance of PCPI in patients with smoldering multiple myeloma (SMM).
- To determine if PCPI can identify SMM patients at higher risk for disease progression.
Main Methods:
- Retrospective review of 306 patients diagnosed with smoldering multiple myeloma.
- Analysis of plasma cell proliferative index (PCPI) levels, categorized as elevated (>0.5) or low.
- Comparison of time to progression and progression rates between patients with elevated and low PCPI.
Main Results:
- Twenty-six percent (79/306) of patients had an elevated PCPI.
- An elevated PCPI was associated with a significantly shorter time to progression (median 3.0 years vs. 7.1 years; P = .0004).
- Patients with elevated PCPI showed a higher progression rate within 24 months (49% vs. 20%; P < .0001).
Conclusions:
- PCPI is a valuable prognostic tool for risk stratifying patients with smoldering multiple myeloma.
- Elevated PCPI identifies patients likely to experience earlier progression, suggesting a need for closer monitoring.
- These findings support considering early intervention trials for SMM patients with an elevated PCPI.
Related Concept Videos
Proliferative Phase
Notably, the stratum basale, the basal layer of the endometrium, including the basal parts of the uterine glands, remains unaffected by menstruation. Stem cells in this layer undergo mitosis, regenerating the stratum functionalis and thickening the...
Introduction to Test of Independence
The test statistic for a test of independence is similar to that of a goodness-of-fit test:
Hypothesis Test for Test of Independence
H0: The two variables (factors)...
Law of Independent Assortment
Independent and Dependent Sources
Independent voltage or current sources supply a fixed amount of voltage or current, respectively, which is unaffected by other elements within the circuit. These are represented using specific symbols. Independent voltage sources are symbolized with polarities (+ and -), indicating the direction of the...
Protein Buffers in Blood Plasma and Cells
Certain amino acids can exist in a zwitterion state at a...

